Business Context and Reporting Period
Company: Purple Innovation, Inc. (PRPL)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Purple is an omni-channel sleep products company known for its proprietary Hyper-Elastic Polymer gel technology. It sells mattresses, pillows, and accessories through Direct-to-Consumer (DTC) channels (e-commerce and showrooms) and wholesale partners. As of December 31, 2024, the company operated 58 showrooms in the U.S.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Net Revenues | $487.9 million | $510.5 million |
| Gross Profit | $181.1 million | $171.8 million |
| Gross Margin | 37.1% | 33.7% |
| Operating Loss | $(92.2) million | $(113.7) million |
| Net Loss (Attributable to Purple Inc.) | $(97.9) million | $(120.8) million |
| Cash and Cash Equivalents | $29.0 million | $26.9 million |
| Net Cash Used in Operating Activities | $(17.9) million | $(54.7) million |
| Total Debt (Related Party Loan) | $70.7 million | $30.0 million |
Note: Debt figures reflect the principal balance of the Related Party Loan as of December 31, 2024, which includes capitalized interest.
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 4.4% to $487.9 million, driven by industry-wide demand softness and a strategic reduction in advertising spend to improve profitability. E-commerce revenue fell 7.7%, while showroom revenue increased 5.8% due to higher average selling prices and product mix shifts.
- Margin Expansion: Gross margin improved to 37.1% from 33.7%, reflecting supply chain efficiencies and operational improvements, despite $15.4 million in restructuring charges recorded in Cost of Revenues.
- Restructuring Plan: In August 2024, the company initiated a plan to consolidate manufacturing by closing two Utah facilities and moving production to Georgia. This resulted in $36.4 million in total charges in 2024 (including $15.4M in COGS and $20.0M in operating expenses), covering accelerated depreciation, asset write-downs, and employee-related costs.
- Debt Refinancing: In January 2024, the company entered an Amended and Restated Credit Agreement, borrowing $61.0 million to refinance existing debt. Interest is paid in-kind (PIK), increasing the principal balance.
Guidance, Outlook, and Risks
Outlook and Strategy
- Product Innovation: The company plans to launch "Rejuvenate 2.0" in Q2 2025 featuring new DreamLayer grid technology.
- Cost Savings: Management expects continued gross margin gains from plant consolidation, supplier diversification, and improved yield results.
- Liquidity: Management concluded the company has sufficient liquidity for at least one year following a March 12, 2025, amendment to the credit agreement that provided an additional $19.0 million term loan.
Risks and Contingencies
- Debt Covenants and Make-Whole Provisions: The credit agreement includes strict covenants and substantial "make-whole" prepayment penalties. Failure to comply could lead to default and acceleration of debt.
- Stock Price and Listing: The company received notice from NASDAQ in November 2024 regarding non-compliance with the $1.00 minimum bid price rule. While compliance was regained in February 2025, the stock price has fluctuated below $1.00, posing a delisting risk.
- Going Concern: The company has a history of recurring operating losses and negative cash flows. While a going concern assessment was passed for the 12-month period following the report date, future liquidity depends on successful execution of cost-saving measures and potential additional financing.
- Concentrated Ownership: Coliseum Capital Management LLC is the largest stockholder and primary lender, exercising substantial control over the board and strategy.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $29.0 million cash balance plus the new $19.0 million loan against the $70.7 million debt principal and ongoing operating cash burn.
- Restructuring Execution: Monitor the timeline for the closure of Utah facilities (planned Q2 2025) and the realization of projected cost savings versus the $4.6 million in remaining estimated charges.
- Debt Terms: Review the specific "make-whole" payment triggers in the March 2025 Amendment to the Credit Agreement and the impact of PIK interest on the growing debt principal.
- NASDAQ Compliance: Track the stock price relative to the $1.00 minimum bid requirement to assess delisting risk.
- Product Launch Impact: Assess the market reception and revenue contribution of the Rejuvenate 2.0 launch in Q2 2025.